Literature DB >> 31821039

Amitriptyline inhibits nonalcoholic steatohepatitis and atherosclerosis induced by high-fat diet and LPS through modulation of sphingolipid metabolism.

Zhongyang Lu1, Yanchun Li2, Wing-Kin Syn1,3,4, Zhewu Wang1,5, Maria F Lopes-Virella1,2, Timothy J Lyons2, Yan Huang1,2.   

Abstract

We reported previously that increased acid sphingomyelinase (ASMase)-catalyzed hydrolysis of sphingomyelin, which leads to increases in ceramide and sphingosine 1 phosphate (S1P), played a key role in the synergistic upregulation of proinflammatory cytokines by palmitic acid (PA), a major saturated fatty acid, and lipopolysaccharide (LPS) in macrophages. Since macrophages are vital players in nonalcoholic steatohepatitis (NASH) and atherosclerosis, we assessed the effect of ASMase inhibition on NASH and atherosclerosis cooperatively induced by high-PA-containing high-fat diet (HP-HFD) and LPS in LDL receptor-deficient (LDLR-/-) mice. LDLR-/- mice were fed HP-HFD, injected with low dose of LPS and treated with or without the ASMase inhibitor amitriptyline. The neutral sphingomyelinase inhibitor GW4869 was used as control. Metabolic study showed that both amitriptyline and GW4869 reduced glucose, lipids, and insulin resistance. Histological analysis and Oil Red O staining showed that amitriptyline robustly reduced hepatic steatosis while GW4869 had modest effects. Interestingly, immunohistochemical study showed that amitriptyline, but not GW4869, strongly reduced hepatic inflammation. Furthermore, results showed that both amitriptyline and GW4869 attenuated atherosclerosis. To elucidate the underlying mechanisms whereby amitriptyline inhibited both NASH and atherosclerosis, but GW4869 only inhibited atherosclerosis, we found that amitriptyline, but not GW4869, downregulated proinflammatory cytokines in macrophages. Finally, we found that inhibition of sphingosine 1 phosphate production is a potential mechanism whereby amitriptyline inhibited proinflammatory cytokines. Collectively, this study showed that amitriptyline inhibited NASH and atherosclerosis through modulation of sphingolipid metabolism in LDLR-/- mice, indicating that sphingolipid metabolism in macrophages plays a crucial role in the linkage of NASH and atherosclerosis.

Entities:  

Keywords:  acid sphingomyelinase; amitriptyline; diabetes; inflammation; nonalcoholic steatohepatitis

Mesh:

Substances:

Year:  2019        PMID: 31821039      PMCID: PMC7052581          DOI: 10.1152/ajpendo.00181.2019

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  58 in total

Review 1.  Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease.

Authors:  Zhang Wenfeng; Wu Yakun; Mu Di; Gong Jianping; Wu Chuanxin; Huang Chun
Journal:  Ann Hepatol       Date:  2014 Sep-Oct       Impact factor: 2.400

2.  The role of sphingolipid metabolism disruption on lipopolysaccharide-induced lung injury in mice.

Authors:  Renata Tiemi Okuro; Mariana Nascimento Machado; Natália Vasconcelos Casquilho; Alcendino Jardim-Neto; Alysson Roncally-Carvalho; Georgia Correa Atella; Walter Araujo Zin
Journal:  Pulm Pharmacol Ther       Date:  2018-04-24       Impact factor: 3.410

Review 3.  Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis.

Authors:  Yoon Seok Roh; Ekihiro Seki
Journal:  J Gastroenterol Hepatol       Date:  2013-08       Impact factor: 4.029

Review 4.  Dietary fatty acids in metabolic syndrome, diabetes and cardiovascular diseases.

Authors:  Giuseppe Cascio; Gabriella Schiera; Italia Di Liegro
Journal:  Curr Diabetes Rev       Date:  2012-01

5.  TLR4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes.

Authors:  Zhongyang Lu; Xiaoming Zhang; Yanchun Li; Maria F Lopes-Virella; Yan Huang
Journal:  Immunobiology       Date:  2015-06-30       Impact factor: 3.144

Review 6.  Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice.

Authors:  Kristiaan Wouters; Ronit Shiri-Sverdlov; Patrick J van Gorp; Marc van Bilsen; Marten H Hofker
Journal:  Clin Chem Lab Med       Date:  2005       Impact factor: 3.694

7.  ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis.

Authors:  Raquel Fucho; Laura Martínez; Anna Baulies; Sandra Torres; Nuria Tarrats; Anna Fernandez; Vicente Ribas; Alma M Astudillo; Jesús Balsinde; Pablo Garcia-Rovés; Montserrat Elena; Ina Bergheim; Sophie Lotersztajn; Christian Trautwein; Hanna Appelqvist; Adrienne W Paton; James C Paton; Mark J Czaja; Neil Kaplowitz; Jose C Fernandez-Checa; Carmen García-Ruiz
Journal:  J Hepatol       Date:  2014-06-16       Impact factor: 25.083

8.  Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Authors:  Rachel M Williamson; Jackie F Price; Stephen Glancy; Elisa Perry; Lisa D Nee; Peter C Hayes; Brian M Frier; Liesbeth A F Van Look; Geoffrey I Johnston; Rebecca M Reynolds; Mark W J Strachan
Journal:  Diabetes Care       Date:  2011-04-08       Impact factor: 19.112

9.  Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.

Authors:  K Kobayashi; N Takahashi; E Jimi; N Udagawa; M Takami; S Kotake; N Nakagawa; M Kinosaki; K Yamaguchi; N Shima; H Yasuda; T Morinaga; K Higashio; T J Martin; T Suda
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

10.  The apolipoprotein-AI mimetic peptide L4F at a modest dose does not attenuate weight gain, inflammation, or atherosclerosis in LDLR-null mice.

Authors:  Michelle M Averill; Eung Ju Kim; Leela Goodspeed; Shari Wang; Savitha Subramanian; Laura J Den Hartigh; Chongren Tang; Yilei Ding; Catherine A Reardon; Godfrey S Getz; Alan Chait
Journal:  PLoS One       Date:  2014-10-06       Impact factor: 3.240

View more
  6 in total

1.  Curcumin alleviates lipopolysaccharides-induced inflammation and apoptosis in vascular smooth muscle cells via inhibition of the NF-κB and JNK signaling pathways.

Authors:  Haohang Ruan; Qing Huang; Benting Wan; Ming Yang
Journal:  Inflammopharmacology       Date:  2022-03-01       Impact factor: 4.473

2.  Inhibition of acid sphingomyelinase by imipramine abolishes the synergy between metabolic syndrome and periodontitis on alveolar bone loss.

Authors:  Yanchun Li; Zhongyang Lu; Lixia Zhang; Cameron L Kirkwood; Keith L Kirkwood; Maria F Lopes-Virella; Yan Huang
Journal:  J Periodontal Res       Date:  2021-11-08       Impact factor: 4.419

3.  The Acid Sphingomyelinase Inhibitor Amitriptyline Ameliorates TNF-α-Induced Endothelial Dysfunction.

Authors:  Yang Ji; Jing Chen; Lihua Pang; Changnong Chen; Jinhao Ye; Hao Liu; Huanzhen Chen; Songhui Zhang; Shaojun Liu; Benrong Liu; Chuanfang Cheng; Shiming Liu; Yun Zhong
Journal:  Cardiovasc Drugs Ther       Date:  2022-09-14       Impact factor: 3.947

4.  Inflammation Induced by Lipopolysaccharide and Palmitic Acid Increases Cholesterol Accumulation via Enhancing Myeloid Differentiation Factor 88 Expression in HepG2 Cells.

Authors:  Junbin Chen; Yuguo Liu; Huiyu Luo; Guoxun Chen; Zhongdaixi Zheng; Tiannan Wang; Xinge Hu; Yue Zhao; Jiaqi Tang; Chuhong Su; Longying Zha
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-30

Review 5.  Molecular Advances in MAFLD-A Link between Sphingolipids and Extracellular Matrix in Development and Progression to Fibrosis.

Authors:  Adrian Kołakowski; Sylwia Dziemitko; Aleksandra Chmielecka; Hubert Żywno; Wiktor Bzdęga; Tomasz Charytoniuk; Adrian Chabowski; Karolina Konstantynowicz-Nowicka
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

Review 6.  Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases.

Authors:  Carolyn Tallon; Kristen R Hollinger; Arindom Pal; Benjamin J Bell; Rana Rais; Takashi Tsukamoto; Kenneth W Witwer; Norman J Haughey; Barbara S Slusher
Journal:  Drug Discov Today       Date:  2021-03-31       Impact factor: 8.369

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.